Clinical Trials Information Treatment 
NORML
MAY 26, 2020
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
NORML
MAY 21, 2019
.” Researchers concluded, “CBD’s potential to reduce cue-induced craving and anxiety provides a strong basis for further investigation of this phytocannabinoid as a treatment option for opioid use disorder.” In clinical models, CBD administration has been shown to reduce cravings for tobacco. .'”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
APRIL 30, 2020
CDC invites comments specifically on topics focused on using or prescribing opioid pain medications, non-opioid medications, or non-pharmacological treatments.” ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy. .”
NORML
MARCH 30, 2020
They reported “circumstantial evidence” suggesting that CBD may possess antiviral acticity in a limited number of conditions, specifically in the treatment of hepatitis C and Karposi sarcoma. Misleading claims represent both a threat to public health and a violation of consumer access to accurate information.”
Cannabis Law Report
JULY 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT WAKE NETWORK, INC.
NORML
JANUARY 31, 2019
Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.
Expert insights. Personalized for you.
247 
Let's personalize your content